Press releases from the 26th EORTC – NCI – AACR symposium on molecular targets in cancer therapeutics in Barcelona
24 Nov 2014
The 26th EORTC – NCI – AACR symposium on molecular targets in cancer therapeutics recently held in Barcelona proved to be a very successful event. Below is a listing of some of the many results announced at this prestigious symposium:
- Early results of new drug, ASP8273, show response in Japanese patients with treatment-resistant non-small cell lung cancer
- Researchers pioneer new approach to treating HPV-related cervical cancer
- Researchers identify biological indicator of response to new ovarian cancer drug
- Early results show response to new drug in patients with lymphomas and advanced solid tumours
- Three drugs may be better than one for certain patients with advanced colorectal cancer
- Trial results show treatment-resistant advanced non-small cell lung cancer responds to new drug, rociletinib
- Patients with advanced papillary kidney cancer respond well to a combination of two existing anti-cancer drugs
- Galeterone shows activity in a variant form of castration-resistant prostate cancer
- First demonstration of anti-cancer activity for AG-120, an inhibitor of the IDH1 mutation, in patients with advanced leukaemia
Related News
EORTC: Advancing research and treatment for rare cancers
29 Feb 2024
EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration
22 Feb 2024
Appointment of Malte Peters as EORTC Strategic Alliance Officer
9 Feb 2024
Unique series of workshops in partnership with the European Medicines Agency (EMA)
7 Feb 2024
EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)
14 Dec 2023
Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023
6 Dec 2023
EORTC Quality of Life measures integrated in CDISC
20 Nov 2023
EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma
7 Nov 2023
Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia
31 Oct 2023
New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023
20 Oct 2023